Voyager Therapeutics, Inc. announced plans during 2018 for Steven Paul, M.D., to transition from president and chief executive officer (CEO) of Voyager Therapeutics to executive science advisor. Dr. Paul is a founder of Voyager, having been with the company for six years since its inception, initially as president of R&D, then as president and CEO since September 2014. In addition to transitioning to an executive science advisor role, in which he will focus on preclinical discovery research and portfolio development, Dr. Paul will continue to serve on Voyager's Board of Directors, and as a member of Voyager's Science & Technology Committee.

Voyager's Board of Directors will conduct a retained search during which time Dr. Paul will remain in his current role until a new CEO has been appointed. Dr. Paul's 35 years of neuroscience expertise includes an extensive track record in CNS drug discovery and development.